Skip to main content
Clinical Trials/NCT02944006
NCT02944006
Unknown
Not Applicable

Establishment of Radiomics Database by Clinical Application of Multiparametric MRI Including DCE-MRI Based on Incoherent Undersampling

Seoul National University Hospital1 site in 1 country29 target enrollmentNovember 28, 2016
ConditionsPancreas Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pancreas Cancer
Sponsor
Seoul National University Hospital
Enrollment
29
Locations
1
Primary Endpoint
T-staging
Last Updated
4 years ago

Overview

Brief Summary

This study aims to establish radiomics database for pancreas cancer from multiparametric MRI including DCE-MRI obtained by using incoherent undersampling and radial acquisition for clinical staging as well as quantitative analysis.

Registry
clinicaltrials.gov
Start Date
November 28, 2016
End Date
November 2023
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jeong Min Lee

Professor

Seoul National University Hospital

Eligibility Criteria

Inclusion Criteria

  • surgical candidate for pancreatico-duodenectomy
  • characteristic finding of pancreatic adenocarcinoma on prior CT or MRI
  • OR histologically diagnosed with pancreatic adenocarcinoma
  • signed for informed consent

Exclusion Criteria

  • under 18 years
  • not eligible for pancreatico-duodenectomy
  • unresectable patients (locally advanced on prior CT/MRI or metastatic disease)
  • tumors with suspicion of other histologic types (neuroendocrine, IPMN, etc)
  • any contra-indication of contrast-enhanced MRI
  • recurred pancreatic cancer

Outcomes

Primary Outcomes

T-staging

Time Frame: 4 weeks after MR acquisition

T-staging of the tumor at MRI.

Secondary Outcomes

  • kurtosis(4 weeks after MR acquisition)
  • mean transit time(4 weeks after MR acquisition)
  • true diffusion(4 weeks after MR acquisition)
  • N-staging(4 weeks after MR acquisition)
  • arterial fraction(4 weeks after MR acquisition)
  • extracellular volume(4 weeks after MR acquisition)
  • perfusion fraction(4 weeks after MR acquisition)
  • arterial blood flow(4 weeks after MR acquisition)
  • pseudodiffusion(4 weeks after MR acquisition)
  • mean diffusivity(4 weeks after MR acquisition)

Study Sites (1)

Loading locations...

Similar Trials